Abstract A growing body of evidence suggests that sodium-glucose cotransporter 2 (SGLT2) inhibitors appear to be a powerful option to improve the cardiovascular (CV) prognosis in high CV-risk patients with type 2 diabetes. Despite a significant reduction in major adverse CV events with SGLT2 inhibitor treatment. however. an unexpected increased risk of amputation was observed in the C... https://toyscyclers.shop/product-category/bicycle-helmets/